PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
The Korean Journal of Medicine10.3904/kjm.2019.94.3.2942019943294-298Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant TuberculosisDong-gon Hyun, Se hee Lee, Kyung-Wook Jo, Tae Sun Shimhttp://ekjm.org/upload/kjm-2019-94-3-294.pdf, http://ekjm.org/journal/view.php?doi=10.3904/kjm.2019.94.3.294, http://ekjm.org/upload/kjm-2019-94-3-294.pdf
Annals of Laboratory Medicine10.3343/alm.2019.39.1.1132019391113Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Koreahttps://synapse.koreamed.org/pdf/10.3343/alm.2019.39.1.113, https://synapse.koreamed.org/DOIx.php?id=10.3343/alm.2019.39.1.113, https://synapse.koreamed.org/DOIx.php?id=10.3343/alm.2019.39.1.113
Drug Development Research10.1002/ddr.214982018Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challengingYang Li, Feng Sun, Wenhong Zhanghttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.21498, https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ddr.21498, https://onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.21498
The Lancet Infectious Diseases10.1016/s1473-3099(18)30106-32018185480-481Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosisMarina Tadolini, Simon Tiberi, Giovanni Battista Migliorihttps://api.elsevier.com/content/article/PII:S1473309918301063?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1473309918301063?httpAccept=text/plain
International Journal of Molecular Sciences10.3390/ijms180203412017182341Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewGiovanni Migliori, Emanuele Pontali, Giovanni Sotgiu, Rosella Centis, Lia D’Ambrosio, Simon Tiberi, Marina Tadolini, Susanna Espositohttp://www.mdpi.com/1422-0067/18/2/341/pdf
Tuberculosis10.1016/j.tube.2018.04.008201811120-30Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)Yongge Liu, Makoto Matsumoto, Hidekaza Ishida, Kinue Ohguro, Masuhiro Yoshitake, Rajesh Gupta, Lawrence Geiter, Jeffrey Hafkinhttps://api.elsevier.com/content/article/PII:S1472979218300489?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1472979218300489?httpAccept=text/plain
Drug Design, Development and Therapy10.2147/dddt.s609232015677Profile of delamanid for the treatment of multidrug-resistant tuberculosisJohn Lynch, John Szumowskihttps://www.dovepress.com/getfile.php?fileID=23455
Annals of Laboratory Medicine10.3343/alm.2018.38.6.5632018386563Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in KoreaJeong Seong Yang, Kyung Jong Kim, Hongjo Choi, Seung Heon Leehttps://synapse.koreamed.org/pdf/10.3343/alm.2018.38.6.563, https://synapse.koreamed.org/DOIx.php?id=10.3343/alm.2018.38.6.563, https://synapse.koreamed.org/DOIx.php?id=10.3343/alm.2018.38.6.563
Drugs & Therapy Perspectives10.1007/s40267-015-0251-820153111378-384Delamanid in multidrug-resistant tuberculosis: a guide to its use in the EUKatherine A. Lyseng-Williamson, Hannah A. Blair, Lesley J. Scotthttp://link.springer.com/content/pdf/10.1007/s40267-015-0251-8.pdf, http://link.springer.com/article/10.1007/s40267-015-0251-8/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40267-015-0251-8
Drugs10.1007/s40265-014-0331-4201475191-100Delamanid: A Review of Its Use in Patients with Multidrug-Resistant TuberculosisHannah A. Blair, Lesley J. Scotthttp://link.springer.com/content/pdf/10.1007/s40265-014-0331-4.pdf, http://link.springer.com/article/10.1007/s40265-014-0331-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40265-014-0331-4